Project 4B: Lower Extremity Strength Training in ICU Patients

NCT02467023 | Completed DMC

• 2 other identifiers: IRB201500109 -NP50GM111152-01
• Study Type: interventional
• Target: 5
• Locations: 1 country
• Sites: 1

Brief Summary

The purpose of this research study is to see if electrical stimulation of the leg muscles will improve strength in patients receiving mechanical ventilation in the intensive care unit (ICU). ICU care frequently results in chronically critically ill (CCI) patients. Some CCI patients develop persistent inflammation/immunosuppression and catabolism syndrome (PICS), and they have morbid long-term outcomes. CCI patients with PICS often develop severe limb muscle atrophy, weakness and accelerated protein catabolism. Limb muscle dysfunction in PICS is due to many factors including sepsis/inflammation, proteolysis, apoptosis, and inactivity. Despite the seriousness of limb muscle weakness in CCI patients receiving mechanical ventilation, little is known about exercise strategies to treat this problem. There is limited knowledge about how strength training impacts inflammation and catabolism in CCI patients. In addition, an assessment of the effect of exercise on markers of inflammation and protein catabolism on muscle samples obtained with biopsy techniques and venous blood samples will be performed. This project will further understanding of how treating CCI-related muscle weakness with strength training cannot only improve muscle function, but also potentially blunt the inflammation and catabolism of PICS.

Conditions

Sepsis

Keywords

chronic critical illness; strength training; exercise; sepsis; mechanical ventilation

Outcome Measures

Primary Outcomes (3)

• Isometric muscle twitch force measured at the start of the study, approximately every seven days thereafter and final day of study.

  Measurement of maximal isometric strength will be done by using a dynamometer.

  Change from days 1, 7, 14, 21, and 28

• Change in inflammatory markers on days 1, 7, 14, 21, and 28.

  blood and urine will be tested for the markers of inflammation. The following will be tested: (IL)-1β, IL-6, IL-8, IL-10, IL-12, (TNF)α, (IFN)γ, (MCP)-1, (IP)10, (SDF)-1, (MIP)1α, (HMG)B1, procalcitonin, and (CRP).

  Change from days 1, 7, 14, 21, and 28

• Change in immunosuppressive markers on days 1, 7, 14, 21, and 28.

  blood and urine will be tested for the markers of immunosuppression. The following will be tested: MDSC phenotype (HLA-DRlow)

  Change from days 1, 7, 14, 21, and 28

Secondary Outcomes (1)

• Measurement of key proteins of mitochondrial function using immunohistochemistry and Western blotting

  Measurement on day 28

Study Arms (2)

effective muscle stimulation group

EXPERIMENTAL

Subjects in this arm will be in the study for up to 28 days or until discharge from the ICU. They will receive lower extremity muscle stimulation with Niveus medical stimulator, multiple measurement of maximal isometric twitch strength, muscle biopsy with muscle biopsy medication fentanyl, muscle biopsy medication versed, muscle biopsy medication lidocaine, and blood and urine sampling.

Device: Muscle stimulation with Niveus medical stimulator; Device: measurement of maximal isometric twitch strength; Procedure: Muscle Biopsy; Drug: Muscle Biopsy Medication: Lidocaine; Drug: Muscle Biopsy Medication: Versed; Drug: Muscle Biopsy Medication: Fentanyl; Other: Blood and Urine Sampling

ineffective muscle stimulation group

ACTIVE COMPARATOR

Subjects assigned to this arm will be studied for up to 28 days or until discharge and will receive a sham muscle stimulation with Niveus medical stimulator, multiple measurement of maximal isometric twitch strength blood and urine samples, and a muscle biopsy sample with muscle biopsy medication fentanyl, muscle biopsy medication versed, and muscle biopsy medication lidocaine.

Device: measurement of maximal isometric twitch strength; Procedure: Muscle Biopsy; Drug: Muscle Biopsy Medication: Lidocaine; Drug: Muscle Biopsy Medication: Versed; Drug: Muscle Biopsy Medication: Fentanyl; Other: Blood and Urine Sampling; Device: ineffective muscle stimulation

Interventions

Muscle stimulation with Niveus medical stimulator DEVICE

Subjects will be treated five days per week, for 30 minutes each session. Muscle stimulation will be conducted for four seconds every 15 seconds, thus the subjects will undergo four stimulations per minute. Muscle stimulation will be adjusted until there is a visible or palpable bilateral quadriceps contraction.

effective muscle stimulation group

measurement of maximal isometric twitch strength DEVICE

Quadriceps strength will be measured on the initial day of study approximately every seven days thereafter and on the final day of study participation. For this measurement, patients will remain supine in their bed and the dominant leg will be placed on a frame that will hold the knee at a 60° angle. A cuff will be placed around the ankle and connected to an electronic dynamometer that will record the force generated during the stimulation. The muscle will be stimulated to contract with magnetic stimulators placed over the body of the quadriceps muscle and stimulated at 100% of power output.

effective muscle stimulation group; ineffective muscle stimulation group

Muscle Biopsy PROCEDURE

This procedure will be done at the end of participation in the study.The biopsy will be performed with a sterile needle, which will be inserted through the skin. A skin incision (approximately 1/4" long) will be made in order to insert the needle. The biopsy procedure yields two small pieces of muscle tissue (200 mg total), each about half the size of the eraser on a pencil. After the biopsy is taken, the incision will be closed using a steri-strip bandage (no stitches are required), and a sterile dressing will be placed over the site to reduce the risk of bleeding.

effective muscle stimulation group; ineffective muscle stimulation group

Muscle Biopsy Medication: Lidocaine DRUG

Biopsy samples will be obtained under local anesthesia (up to 20 milliliters of 1% Lidocaine administered subcutaneously). Lidocaine, a drug to numb your pain will be injected into the skin and muscle tissue. The injection of the numbing medication will be slightly painful and is similar to receiving a shot into your arm for a vaccination. This medication numbs the skin and muscle so that you do not feel pain when the biopsy is obtained.

Also known as: Lidocaine for biopsy

effective muscle stimulation group; ineffective muscle stimulation group

Muscle Biopsy Medication: Versed DRUG

Prior to starting the muscle biopsy, you can receive a drug, Versed, to help you relax during the procedure. 1-2 milligrams of Versed will be administered intravenously (in the vein) through an existing peripheral or central intravenous catheter. This procedure drug is given as needed and can be repeated one time as needed.

Also known as: Versed for biopsy

effective muscle stimulation group; ineffective muscle stimulation group

Muscle Biopsy Medication: Fentanyl DRUG

Prior to starting the muscle biopsy, you can receive a drug, Fentanyl, to make you more comfortable during the procedure. 50-100 micrograms of Fentanyl will be administered intravenously (in the vein) through an existing peripheral or central intravenous catheter. This procedure drug is given as needed and can be repeated one time as needed.

Also known as: Fentanyl for biopsy

effective muscle stimulation group; ineffective muscle stimulation group

Blood and Urine Sampling OTHER

Blood and urine samples will be obtained and examined for markers inflammation and muscle catabolism. Sampling will occur at time of entry into study, and then once every 2-4 days and on the final day of participation or the last day of study (day 28). Peripheral blood will be collected from an existing venous line, or by venipuncture, if required. Urine will be collected from an existing catheter or if the patient is able to void on their own then we will provide a specimen cup. There will be no more than 14 ml of blood drawn at any given time point and a collection of 15 ml of urine at each time point.

effective muscle stimulation group; ineffective muscle stimulation group

ineffective muscle stimulation DEVICE

An investigator will perform range of motion on both legs, five days per week. The range of motion activity will include the investigator helping you bend and straighten each knee approximately 12 times. Rotation of the leg at the hip will also be performed by bending your knee and gently rotating your upper leg in a clockwise and counterclockwise motion. The range of motion will be performed on each leg and repeated five days per week.

ineffective muscle stimulation group

Eligibility Criteria

• Age: 18 Years+
• Sex: all
• Healthy Volunteers: No
• Age Groups: Adult (18-64), Older Adult (65+)

You may qualify if:

• Presence in the surgery or trauma ICU,
• age of ≥18 years,
• received MV for 3 day and expected to survive ICU stay,
• ability to obtain informed consent from patient or legally authorized representative,
• approval of an ICU attending for patient to participate.

You may not qualify if:

• Have an uncontrollable source of sepsis (e.g., irreversible disease state, unresectable dead bowel),
• are receiving "comfort care" or have advanced care directives limiting resuscitative efforts,
• have an implanted electronic device (pacemaker/defibrillator/insulin pump, etc.)
• have known HIV infection with CD4 count \< 200 cells/mm3,
• are organ transplant recipients on immunosuppressive agent(s),
• have a known pregnancy,
• history of stroke with weakness,
• Inability to walk without assistance prior to ICU admission (excluding the use of cane or walker)
• lower-extremity amputations, rheumatic or severe osteoarthritis of any joint in the lower extremity,
• Unrepaired hip fracture, unstable cervical spine or other bone diseases
• arterial or venous insufficiency in the lower extremity,
• have prior arrangements to be transferred to other facilities before 28 days of treatment,
• have an unstable or "difficult airway" at 14 days of ICU care, predicted to last for more than 72 hours,
• are on vasopressor or vasodilatory agents as a continuous infusion at more than a "renal dose,"
• have severe cardiac dysrhythmias,

Sponsors & Collaborators

• University of Florida: lead
• National Institutes of Health (NIH): collaborator
• National Institute of General Medical Sciences (NIGMS): collaborator

Study Sites (1)

UF Health Shands Hospital at the University of Florida

Gainesville, Florida, 32610, United States

Location

MeSH Terms

Conditions

Sepsis; Motor Activity

Interventions

Lidocaine; Biopsy; Midazolam; Fentanyl; Blood Specimen Collection

Condition Hierarchy (Ancestors)

Infections; Systemic Inflammatory Response Syndrome; Inflammation; Pathologic Processes; Pathological Conditions, Signs and Symptoms; Behavior

Intervention Hierarchy (Ancestors)

Acetanilides; Anilides; Amides; Organic Chemicals; Aniline Compounds; Amines; Cytodiagnosis; Cytological Techniques; Clinical Laboratory Techniques; Diagnostic Techniques and Procedures; Diagnosis; Specimen Handling; Diagnostic Techniques, Surgical; Surgical Procedures, Operative; Investigative Techniques; Benzodiazepines; Benzazepines; Heterocyclic Compounds, 2-Ring; Heterocyclic Compounds, Fused-Ring; Heterocyclic Compounds; Piperidines; Heterocyclic Compounds, 1-Ring; Punctures

Study Officials

• Daniel Martin, PhD, PT

  University of Florida

  PRINCIPAL INVESTIGATOR

Study Design

• Study Type: interventional
• Phase: not applicable
• Allocation: RANDOMIZED
• Masking: NONE
• Purpose: TREATMENT
• Intervention Model: PARALLEL
• Sponsor Type: OTHER
• Responsible Party: SPONSOR

Study Record Dates

• First Submitted: May 19, 2015
• First Posted: June 9, 2015
• Study Start: September 1, 2015
• Primary Completion: July 7, 2016
• Study Completion: July 15, 2016
• Last Updated: January 19, 2018

Record last verified: 2018-01

Locations

US (1)